Cargando…
Trends of denosumab-related publications in web of science
Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. T...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876013/ https://www.ncbi.nlm.nih.gov/pubmed/36705356 http://dx.doi.org/10.1097/MD.0000000000032784 |
_version_ | 1784878075217969152 |
---|---|
author | Jiang, Xiaohong Xie, Tianyu Feng, Wenyu Qin, Zhaojie Liao, Shijie Liu, Yun Lu, Shenglin He, Mingwei Wei, Qingjun |
author_facet | Jiang, Xiaohong Xie, Tianyu Feng, Wenyu Qin, Zhaojie Liao, Shijie Liu, Yun Lu, Shenglin He, Mingwei Wei, Qingjun |
author_sort | Jiang, Xiaohong |
collection | PubMed |
description | Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. This study assessed the course of research and development for denosumab in terms of publications over the past 2 decades. Web of Science databases were searched to identify publications related to research on denosumab from January 1, 2005 to December 31, 2022. The VOS Viewer software (version 1.6.17) and Bibliometrix package in R (version 4.1.3) were used in this study. There were 5119 denosumab-related publications during this period. The total number of citations of denosumab-related publications reached 94917. The most articles were published in the field of Endocrinology Metabolism. As an international language, English remains the most popular language for writing papers. Five of the top ten institutions originated in the USA. Through the VOS Viewer analysis, we found that the relationships between Amgen Inc. with its collaborations were grouped into 4 clusters, the USA was the mainland for research and development on denosumab, closely collaborating with many other countries, such as Canada, Japan, England, and China. Wagman RB from USA was the most prolific author with 119 publications. The journal with the most publications was Osteoporosis International (481 publications). The most cited article was “Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis” with 2053 citations. The clinical trial comprised 6 of the 10 most frequently cited publications, and the rest consisted of reviews. The most frequent keywords for publications since January 1, 2014 were “prevention” and “management,” indicating that a number of prevention and management measures have been developed to regulate the use of denosumab in treating osteoporosis. Our research provided a comprehensive review of denosumab-related publications, suggesting that the development of denosumab is a long process and numerous clinical trials have been conducted before applications in clinical settings. |
format | Online Article Text |
id | pubmed-9876013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-98760132023-01-27 Trends of denosumab-related publications in web of science Jiang, Xiaohong Xie, Tianyu Feng, Wenyu Qin, Zhaojie Liao, Shijie Liu, Yun Lu, Shenglin He, Mingwei Wei, Qingjun Medicine (Baltimore) 7400 Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. This study assessed the course of research and development for denosumab in terms of publications over the past 2 decades. Web of Science databases were searched to identify publications related to research on denosumab from January 1, 2005 to December 31, 2022. The VOS Viewer software (version 1.6.17) and Bibliometrix package in R (version 4.1.3) were used in this study. There were 5119 denosumab-related publications during this period. The total number of citations of denosumab-related publications reached 94917. The most articles were published in the field of Endocrinology Metabolism. As an international language, English remains the most popular language for writing papers. Five of the top ten institutions originated in the USA. Through the VOS Viewer analysis, we found that the relationships between Amgen Inc. with its collaborations were grouped into 4 clusters, the USA was the mainland for research and development on denosumab, closely collaborating with many other countries, such as Canada, Japan, England, and China. Wagman RB from USA was the most prolific author with 119 publications. The journal with the most publications was Osteoporosis International (481 publications). The most cited article was “Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis” with 2053 citations. The clinical trial comprised 6 of the 10 most frequently cited publications, and the rest consisted of reviews. The most frequent keywords for publications since January 1, 2014 were “prevention” and “management,” indicating that a number of prevention and management measures have been developed to regulate the use of denosumab in treating osteoporosis. Our research provided a comprehensive review of denosumab-related publications, suggesting that the development of denosumab is a long process and numerous clinical trials have been conducted before applications in clinical settings. Lippincott Williams & Wilkins 2023-01-27 /pmc/articles/PMC9876013/ /pubmed/36705356 http://dx.doi.org/10.1097/MD.0000000000032784 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 7400 Jiang, Xiaohong Xie, Tianyu Feng, Wenyu Qin, Zhaojie Liao, Shijie Liu, Yun Lu, Shenglin He, Mingwei Wei, Qingjun Trends of denosumab-related publications in web of science |
title | Trends of denosumab-related publications in web of science |
title_full | Trends of denosumab-related publications in web of science |
title_fullStr | Trends of denosumab-related publications in web of science |
title_full_unstemmed | Trends of denosumab-related publications in web of science |
title_short | Trends of denosumab-related publications in web of science |
title_sort | trends of denosumab-related publications in web of science |
topic | 7400 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876013/ https://www.ncbi.nlm.nih.gov/pubmed/36705356 http://dx.doi.org/10.1097/MD.0000000000032784 |
work_keys_str_mv | AT jiangxiaohong trendsofdenosumabrelatedpublicationsinwebofscience AT xietianyu trendsofdenosumabrelatedpublicationsinwebofscience AT fengwenyu trendsofdenosumabrelatedpublicationsinwebofscience AT qinzhaojie trendsofdenosumabrelatedpublicationsinwebofscience AT liaoshijie trendsofdenosumabrelatedpublicationsinwebofscience AT liuyun trendsofdenosumabrelatedpublicationsinwebofscience AT lushenglin trendsofdenosumabrelatedpublicationsinwebofscience AT hemingwei trendsofdenosumabrelatedpublicationsinwebofscience AT weiqingjun trendsofdenosumabrelatedpublicationsinwebofscience |